Exclusion of Htra2-beta1, an up-regulator of full-length SMN2 transcript, as a modifying gene for spinal muscular atrophy - PubMed (original) (raw)

Exclusion of Htra2-beta1, an up-regulator of full-length SMN2 transcript, as a modifying gene for spinal muscular atrophy

C Helmken et al. Hum Genet. 2000 Dec.

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by homozygous mutations of the survival motor neuron gene 1 (SMN1). In rare cases sibs with identical 5q13-homologs and identical SMN1 mutations can show variable phenotypes from unaffected to affected, suggesting the influence of modifying genes. SMN is part of an 800 kDa macromolecular complex that plays an essential role in snRNP biogenesis and pre-mRNA splicing. Due to a single nucleotide difference within SMN1 exon 7 that disrupts an exonic splicing enhancer (ESE), SMN2, a nearly identical copy of SMN1, predominantly expresses alternatively spliced transcripts lacking exon 7, whereas SMN1 mainly produces full-length transcripts. The SR-like trans-acting splicing factor Htra2-beta1 was shown to interact with this ESE and to restore full-length SMN2 expression in vivo in a concentration-dependent manner. Since Htra2-beta1 prevents skipping of exon 7 it is obvious to ask whether mutations within Htra2-beta1 are responsible for the intrafamilial variability of the SMA phenotype. We sequenced either RT-PCR products or genomic DNA covering the complete coding region of Htra2-beta1 as well as the putative promoter of 36 sibs belonging to 15 SMA families with discordant phenotypes but identical genotypes. Neither a mutation nor a polymorphism was found within Htra2-beta1. Additionally, we performed quantitative analysis of Htra2-beta isoforms from 26 sibs without identifying any significant difference between phenotypically discordant sibs. Based on these data, we suggest that the intrafamilial phenotypic variability in SMA families is not caused by polymorphic variants or transcription differences within Htra2-beta1.

PubMed Disclaimer

Similar articles

• Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1.
  Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnik-Schöneborn S, Zerres K, Wirth B. Helmken C, et al. Hum Genet. 2003 Dec;114(1):11-21. doi: 10.1007/s00439-003-1025-2. Epub 2003 Oct 1. Hum Genet. 2003. PMID: 14520560
• Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).
  Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Hofmann Y, et al. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9618-23. doi: 10.1073/pnas.160181697. Proc Natl Acad Sci U S A. 2000. PMID: 10931943 Free PMC article.
• hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1.
  Hofmann Y, Wirth B. Hofmann Y, et al. Hum Mol Genet. 2002 Aug 15;11(17):2037-49. doi: 10.1093/hmg/11.17.2037. Hum Mol Genet. 2002. PMID: 12165565
• Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.
  Wirth B. Wirth B. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Jun;3(2):87-95. doi: 10.1080/146608202760196057. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002. PMID: 12215230 Review.
• Spinal muscular atrophy: from gene to therapy.
  Wirth B, Brichta L, Hahnen E. Wirth B, et al. Semin Pediatr Neurol. 2006 Jun;13(2):121-31. doi: 10.1016/j.spen.2006.06.008. Semin Pediatr Neurol. 2006. PMID: 17027862 Review.

Cited by

• Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on Survival Motor Neuron 2 (SMN2) mRNA Splicing and Expression.
  Kanda S, Moulton E, Butchbach MER. Kanda S, et al. Mol Pharmacol. 2022 Aug;102(2):92-105. doi: 10.1124/molpharm.122.000529. Epub 2022 Jun 6. Mol Pharmacol. 2022. PMID: 35667685 Free PMC article.
• High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice.
  Chen YC, Chang JG, Jong YJ, Liu TY, Yuo CY. Chen YC, et al. PLoS One. 2015 Mar 17;10(3):e0120721. doi: 10.1371/journal.pone.0120721. eCollection 2015. PLoS One. 2015. PMID: 25781985 Free PMC article.
• Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1.
  Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnik-Schöneborn S, Zerres K, Wirth B. Helmken C, et al. Hum Genet. 2003 Dec;114(1):11-21. doi: 10.1007/s00439-003-1025-2. Epub 2003 Oct 1. Hum Genet. 2003. PMID: 14520560
• Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.
  Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Feldkötter M, et al. Am J Hum Genet. 2002 Feb;70(2):358-68. doi: 10.1086/338627. Epub 2001 Dec 21. Am J Hum Genet. 2002. PMID: 11791208 Free PMC article.

References

1. 1. Neuromuscul Disord. 1992;2(5-6):423-8 - PubMed
2. 1. Neuroepidemiology. 1999;18(5):265-9 - PubMed
3. 1. Cell. 1995 Jan 13;80(1):155-65 - PubMed
4. 1. Hum Mol Genet. 1999 Jul;8(7):1177-83 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9004-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program